Vesugen 50mg

Vesugen (50mg) is supplied as a lyophilized powder for use in regulated laboratory environments. Vesugen is a synthetic tripeptide bioregulator composed of lysine–glutamic acid–aspartic acid (Lys–Glu–Asp; KED), originally derived from vascular tissue extracts.

In preclinical research, Vesugen is primarily investigated for its effects on vascular endothelial regulation, gene expression control, and metabolic homeostasis pathways. Reported neural effects are considered indirect and are examined in the context of vascular support and cerebral perfusion, rather than direct neuronal signaling.

• Amino Acid Sequence: Lys–Glu–Asp (KED)
• Peptide Class: Synthetic linear tripeptide bioregulator
• Molecular Formula: C₁₅H₂₆N₄O₈
• Molecular Weight: 390.39 g/mol
• PubChem CID: 87571363
• Synonyms: Lysylglutamyl aspartic acid, SCHEMBL3767701, CHEBI:159909
• Structural Characteristics: Reported as a linear peptide in supplier specifications, supporting predictable use in molecular and transcriptional assays
• Format: High-purity, lyophilized peptide suitable for controlled laboratory workflows

The Vesugen peptide (KED) is examined in preclinical systems for its involvement in vascular and metabolic regulatory pathways, with mechanistic studies focusing on defined molecular targets rather than generalized signaling activity.

Investigated mechanisms include:

• Sirtuin 1 (SIRT1) modulation, linked to mitochondrial function, metabolic regulation, and cellular longevity pathways
• Endothelin signaling, associated with vascular tone and endothelial function
• Oxidative stress response enzymes, examined in antioxidant defense and redox balance models
• Apoptosis control pathways, evaluated through markers of cell survival and programmed cell death
• Ki-67 expression, used as an indicator of cellular proliferation
• Metabolic homeostasis pathways, including energy metabolism and cellular adaptation under stress conditions

These pathways are studied under controlled conditions to evaluate transcriptional regulation and cell-state modulation relevant to vascular biology.

Vesugen is supplied exclusively for laboratory research and is commonly utilized in:

• Endothelial cell proliferation and gene expression studies
• Vascular function and endothelial signaling research
• Sirtuin-associated metabolic pathway investigations, including SIRT1-linked energy regulation
• Oxidative stress and hypoxia-response models
• Epigenetic regulation and transcriptional control assays

Neural research involving Vesugen is limited and typically framed within vascular support mechanisms rather than direct neuronal signaling effects.

Laboratories that order Vesugen peptide generally employ it for mechanistic molecular analysis, not therapeutic exploration.

In preclinical research settings, Vesugen has been applied at concentrations selected based on the experimental design and model type.

• In vitro studies: Commonly use nanomolar to micromolar ranges to assess gene expression, SIRT1 activity, oxidative stress markers, and proliferation indices
• Animal studies: Examine vascular, metabolic, and cell-survival signaling under controlled experimental conditions

Observed outcomes in laboratory models include changes in endothelial gene expression, modulation of oxidative stress responses, altered proliferation markers, and metabolic pathway regulation.

All findings derive exclusively from in vitro and animal research systems. Human dosing has not been established.

When Vesugen is still in its lyophilized or unopened state:

• Store at –20 °C for long-term stability
• Short-term storage at 2–8 °C is acceptable

After reconstitution:

• Refrigerate at 2–8 °C
• Use within 7–10 days

Allow vials to reach room temperature before opening to prevent moisture condensation. Moreover, protect them from light and humidity to preserve peptide integrity

Researchers who buy Vesugen peptide must comply with all applicable institutional, regulatory, and laboratory safety requirements.

References

https://pubmed.ncbi.nlm.nih.gov/19830585/

https://www.mdpi.com/1420-3049/26/22/7053

https://pubmed.ncbi.nlm.nih.gov/25051766/

https://khavinson.info/assets/files/2008-Kozina.pdf

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.